Novo Nordisk Articles
Novo Nordisk’s first nine months 2010 sales grew 17%, beating forecasts, driven by Victoza, NovoRapid and Levemir; NICE backs Victoza
27 October 2010
Impact of Avandia restrictions could benefit Januvia, Byetta and Victoza, US physician survey reveals
7 October 2010
New data on Boehringer Ingelheim’s linagliptin, Novo Nordisk’s degludec and Merck & Co’s Januvia presented at EASD
23 September 2010
Type 2 diabetes drug market to nearly double to $36 billion in 2019, boosted by news drugs; research shows many patients not taking their insulin
23 September 2010
Positive new data on diabetes drugs from Novo Nordisk, AstraZeneca/B-MS and Sanofi-Aventis presented at EASD meeting
21 September 2010
Bristol-Myers Squibb buys ZymoGenetics for $855 million
8 September 2010
Tough road ahead for some generics after USA’s Federal Circuit Patent Use Code decisions
7 September 2010
Novo Nordisk beats forecasts, posting 19% jump in first-half 2010 net profit as sales grow 14%
5 August 2010
Roche/Ipsen’s diabetes drug taspoglutide stumbles on safety grounds, meaning delay in approval
21 June 2010
UK’s NICE backs Novo Nordisk’s Victoza in revised preliminary recommendation; firm discontinues some products in UK
15 June 2010
Two Danish drugmakers - Novo Nordisk and LEO Pharma - say “no” to Greek price cuts order
1 June 2010
Novo Nordisk reports new data demonstrating superior efficacy of Victoza over Januvia in type 2 diabetes
23 April 2010
US FDA exec questions safety of Lilly and Amylin’s Byetta, saying it may pose cancer risk
12 April 2010
EMEA recalls batches of generic Plavix; Sun Pharma withdraws EU marketing application for Repaglinide SUN
26 March 2010
Big pharma struggles to benefit from increased CVD drug usage in market set to grow to $107 billion in 2018
3 March 2010
Denmark’s Novo Nordisk debuts Victoza in the USA, aiming for $1 billion global sales by 2015
17 February 2010
UK’s NICE backs use of Novo Nordisk’s Victoza for diabetes, but only as triple therapy
15 February 2010
FDA approves Novo Nordisk’s new type 2 diabetes drug Victoza
26 January 2010
EU Commission delays decision on Abbott’s acquisition of Solvay; clears Archimedes takeover
25 January 2010
Diabetes and pre-diabetes in USA accounted for $218 billion in costs in 2007, study shows
14 January 2010
Pfizer licenses MultiStem IBD drug from Athersys for as much as $111 million; sells Vicuron subsid
22 December 2009
Roche/Ipsen’s taspoglutide meets Ph III primary endpoints against Lantus and placebo in patients with high BMI
18 December 2009
Pharma market in Denmark expected to grow at 8% pa through 2014
15 December 2009
Scottish Medical Consortium backs use of Novo Nordisk’s Victoza for type 2 diabetics
9 December 2009
Novo Nordisk’s third-quarter 2009 profit rises 3%
2 November 2009
Novo Nordisk initiates new Levemir study
5 June 2009
Bionovo names Klaus Kohl CTO
4 June 2009
Novartis, Novo, Lilly, BI breach ABPI Code
1 June 2009
Novo Nordisk's Levemir lowers ave blood sugar
14 May 2009
Novo Nordisk
7 May 2009
Sales up 18% in 1st qtr for Novo Nordisk
5 May 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Stock Commentary - New York week to Aug 15
8 April 2009
Novo shares plunge on panel liraglutide tie
3 April 2009
More strong results for Novo's liraglutide
27 March 2009
Nordisk's liraglutide reduces HbA1c
23 March 2009
Stock Commentary - New York week to Feb 23, 2009
2 March 2009
Action Pharma names Torben Laursen as VP of business development
23 February 2009
Novo Nordisk promotes Andy Ajello to VP, national diabetes sales
23 February 2009
PrandoiMet launched in USA
16 February 2009
Liraglutide combos see greater HbA1c drop
16 February 2009
Novo Nordisk profits up 13% on insulin sales
9 February 2009
Emergency listing of HIV drugs in Japan
26 January 2009
Highlights of first PDCO meeting of 2009
26 January 2009
Report says Novo and US Merck will top 2014 metabolism market
12 January 2009
Novo Nordisk and VLST collaborate
22 December 2008
Novo partners with Merrion over Insulin analogs
15 December 2008
UPDATE: PDCO has good news for Lux Bio and others
8 December 2008
Japan's doctors want new drugs developed
8 December 2008
FDA updates on delay for Nordisk's liraglutide
24 November 2008
Antyra gets rights to Novo cancer agents
24 November 2008
Novo to invest $400M in China insulin plant
17 November 2008
Amylin shares plunge 26% on possible Byetta LAR US approval delay
10 November 2008
Pharma industry facing a lot of challenges, but there are opportunities, says Novo exec
10 November 2008
Novo Nordisk profit up 22% in 3rd qtr 2008
10 November 2008
Novo enters diabetes stem cell R&D alliance
3 November 2008
Novo's liraglutide achieves greater glycemic control than Amylin/Lilly's Byetta in LEAD 6
27 October 2008
Neose sells assets to Novo, BioGeneriX
29 September 2008
Novo Nordisk changes NovoSeven formulation
22 September 2008
NovoMix 30 leads to 2.4% HbA1c drop in insulin-naive patients.
15 September 2008
Liraglutide improves multiple endpoints in LEAD-4
15 September 2008
Stock Commentary - New York week to Aug 25, 2008
1 September 2008
UPDATE: FDA considering strong warning on Byetta; potential fall-out for all GLP-1s
1 September 2008
Novo Nordisk's 2nd-qtr 2008 profit falls 32%
18 August 2008
Novo Nordisk employee suspended after insider trading
4 August 2008
Novo Nordisk enters deal with Emisphere
30 June 2008
Novo Nordisk discontinues Ph III NovoSeven trial
16 June 2008
Liraglutide superior to Byetta: LEAD study
16 June 2008
Levemir comparable to glargine in control and DACON
16 June 2008
NovoMix 30 cuts HbA1c 2.6% in IMPROVE trial
16 June 2008
Novo Nordisk's liraglutide superior to glimepiride
16 June 2008
Novo Nordisk submits US NDA for GLP-1
2 June 2008
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
